Study summary

The purpose of the trial is to assess the immunological effects and their kinetics, the safety and activity of IMAB362 plus Zoledronic acid with/without low to intermediate doses of Interleukin-2 in subjects with advanced gastroesophageal cancer.

Additional Study Details

Phase
1
Product
N/A
Product
IMAB362
Zoledronic acid
Interleukin-2 (1 million IU)
Interleukin-2 (3 million IU)
Type
Interventional
Masking
N/A
Enrollment number
32
Show Additional Study Details

Get more information

Would you like more information about clinical trial sites that are recruiting participants for Safety and activity of IMAB362 in combination with zoledronic acid and interleukin-2 in CLDN18.2-positive Gastric Cancer? Contact us by filling out your information to the right and we’ll respond to you.

  • A caregiver
  • A healthcare provider
  • A parent
  • A patient
  • A patient advocate
  • Algeria
  • Argentina
  • Armenia
  • Australia
  • Austria
  • Belarus
  • Belgium
  • Bosnia And Herzegovina
  • Brazil
  • Bulgaria
  • Canada
  • Chile
  • China
  • Colombia
  • Croatia
  • Czech Republic
  • Denmark
  • Dominican Republic
  • Egypt
  • Estonia
  • Finland
  • Former Serbia and Montenegro
  • France
  • Georgia
  • Germany
  • Greece
  • Guatemala
  • Hong Kong
  • Hungary
  • Iceland
  • India
  • Indonesia
  • Ireland
  • Israel
  • Italy
  • Japan
  • Jordan
  • Kazakhstan
  • Latvia
  • Lebanon
  • Lithuania
  • Macedonia
  • Malaysia
  • Mexico
  • Montenegro
  • Morocco
  • Netherlands
  • New Zealand
  • Norway
  • Panama
  • Peru
  • Philippines
  • Poland
  • Portugal
  • Puerto Rico
  • Republic of Korea
  • Republic of Moldova
  • Romania
  • Russian Federation
  • Saudi Arabia
  • Serbia
  • Singapore
  • Slovakia
  • Slovenia
  • South Africa
  • Spain
  • Sweden
  • Switzerland
  • Taiwan, Province of China
  • Thailand
  • Turkey
  • Ukraine
  • United Kingdom
  • United States
  • Vietnam

By clicking ["Continue/Submit"], you agree that Astellas may contact you by email with information to help you connect with clinical trial sites. While we can connect you to clinical trial sites, we cannot answer questions about any investigational therapy through email. Your consent to receiving emails is not a requirement to participate in a clinical trial or study. For more information, including how to unsubscribe at any time, see our Privacy Notice & Cookies Policy.

    Locations

    Contact Us
    Contact Us
    Recruiting
    Freiburg University Medical Center, Department of Internal Medicine II, Gastroenterology and Hepatology
    Freiburg, Germany, 79106
    Recruiting
    University Hospital Tuebingen, Department of Internal Medicine I - Gastroenterology, Hepatology, Infectious Diseases
    Tübingen, Germany, 72076
    Recruiting
    Piejuras Hospital, Oncology Clinic
    Liepaja, Latvia, 3401
    Withdrawn
    Military Medical Academy - Multiprofile Hospital for Active Treatment, Sofia, Department of Medical Oncology
    Sofia, Bulgaria, 1606
    Active, not recruiting
    Institut für Klinische Forschung, Krankenhaus Nordwest GmbH
    Frankfurt, Hessen, Germany, 60488
    Withdrawn
    University Hospital Halle (Saale), Department of Internal Medicine IV
    Halle, Germany, 06120
    Recruiting
    BAG / Onkologische Schwerpunktpraxis
    Dresden, Sachsen, Germany, 01307
    Recruiting
    Riga East University Hospital, LLC, Latvian Oncology Center
    Riga, Latvia, LV1038
    Withdrawn
    Hospital Znojmo, Department of Radiation and Clinical Oncology
    Znojmo, Czech Republic, 66902
    Withdrawn
    Multiprofile Hospital for Active Treatment "Sveta Marina", Varna, Clinic of Medical Oncology
    Varna, Bulgaria, 9010
    Recruiting
    Leipzig University Hospital, University Cancer Center (UCCL)
    Leipzig, Germany, 04109
    Withdrawn
    University Multiprofile Hospital for Active Treatment "Tsaritsa Yoanna - ISUL", Sofia, Clinic of Medical Oncology
    Sofia, Bulgaria, 1527
    Recruiting
    Ulm University Hospital, Center for Internal Medicine
    Ulm, Germany, 89070
    Recruiting
    Charité Universitätsmedizin Berlin - CVK, Med. Klinik m.S. Hämatologie und Onkologie
    Berlin, Berlin, Germany, 13353
    Withdrawn
    University Hospital Motol, Department of Radiotherapy and Oncology
    Prague, Czech Republic, 15006

    Frequently Asked Questions

    Are clinical trials only for people with advanced cancer?

    While some clinical trials may focus on more advanced cancers, many trials are open to patients at various stages of their cancer. Each study has rules about who can take part. For example, only patients in a certain age group or those who have a certain type of tumor may be able to join.

    Will I have to stop my current treatment to participate in a clinical trial?

    Sometimes researchers want participants to keep taking their current treatments during a clinical trial. Other times, you may need to stop your current treatments for a while. If the investigational treatment doesn't work, you can usually go back to your original treatment plan.

    Should I be worried about getting a placebo?

    In cancer clinical trials, a placebo is only used if there is no other treatment for that type of cancer. This helps compare an investigational treatment to the placebo. Placebos are rarely used in cancer trials because the best available treatment, called the “standard of care”, is usually given instead.

    Do I need a referral from my doctor to take part in a study?

    Your doctor may not know about all the opportunities for clinical trials that are available to you. Talk to your doctor or other medical provider about clinical trial information that you find. They can help you decide if a clinical trial is right for you. If you do not find any options on this website, we recommend you visit an online public registry website like clinicaltrials.gov to see a wide variety of available clinical trials.

    Explore More

    1

    What are clinical trials?

    2

    Why are Clinical Trials Important?

    3

    Why Participate in a Clinical Trial?